Latest Breaking News On - Clinical economics - Page 1 : comparemela.com

No, Biologics Are Not Natural Monopolies By Robert Popovian, Pharm.D., MS, and Wayne Winegarden, Ph.D. Biologics are not natural monopolies, as certain individuals continually assert. This assertion threatens future innovations, greater healthcare affordability, and patient access. It is well understood that biologics have improved our ability to treat diseases such as cancer and autoimmune ailments. Biologics are also expensive; they now represent 43% of invoice spending, and spending has been growing 14.6% annually over the past five years. Until recently, originator biologics lacked any meaningful competition from less costly off-patent generic copies better known as biosimilars. The biosimilar market in the U.S. has developed slower than expected in some therapeutic areas and far faster in others compared to the European market, which began the introduction of biosimilars a decade earlier.

United statesWayne winegardenRobert popovianUs congressHealth science journalProgressive policy institutePacific research instituteOutcomes researchCenters for medicareGlobal healthy living foundationMedicaid servicesProgressive policyClinical economicsHealth scienceMedical economicsPacific research